Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577589 | 0.80 | MAPT (0.47) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL12326165 | 0.78 | MAPT (0.56) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL29697785 | 0.78 | MAPT (0.56) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL5578613 | 0.74 | MAPT (0.50) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL31401478 | 0.70 | MAPT (0.54) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL2494112 | 0.70 | MAPT (0.54) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL28487175 | 0.69 | MAPT (0.49) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL3924409 | 0.69 | MAPT (0.57) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL5578518 | 0.69 | DYRK1A (0.51) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| Water SCHEMBL8845490 | 0.68 | MAPT (0.56) | MAPTKDM4ESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-7125845-B2 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005010029-A1 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | VIP, CTSC, DPP4 | MAPT 4684/4885KDM4E 452/4885SMN1; SMN2 3463/4885 |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | VIP, CTSC, PRSS1 | MAPT 4748/4885KDM4E 510/4885SMN1; SMN2 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.